Use of antiseptic active principles in pmma bone cements

• US 20060275339A1
• Filed: 07/16/2004
• Published: 12/07/2006
• Est. Priority Date: 07/18/2003
• Status: Abandoned Application

• Current Assignee: Biomet Deutschland GmbH (Zimmer Biomet Holdings, Inc.)
• Original Assignee: Biomet Deutschland GmbH (Zimmer Biomet Holdings, Inc.)
• Inventors: Schilke, Frank, Nies, Berthold, Pietsch, Hanns
• Application Number:
  US10/564,372
• Publication Number:
  US 20060275339A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61L 2300/206 Biguanides, e.g. chlorohexidine
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 24/0015 Medicaments; Biocides
• CPC Class Codes: A61L 24/06 obtained by reactions only involving carbon-to-carbon unsaturated bonds A61L24/043, A61L24/046 take precedence
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: C08L 33/12 Homopolymers or copolymers of methyl methacrylate

Abstract

The invention concerns the use of polyhexamethylene biguanide in PMMA bone cements, which preferably do not contain antibiotics. The cements exhibit a concentration of active principle not exceeding 1 wt. % relative to the total weight of the cement, which is a concentration sufficiently high to prevent microbial colonization of the cement surface. The cements do not cause durable alteration of the healing process.

Claims

1-6. -6. (canceled)

7. A method of preventing microbial colonization of a polymethyl methacrylate (PMMA) bone cement surface, comprising the step of admixing polyhexamethylene biguanide with a PMMA bone cement, wherein the active principle concentration of the polyhexamethylene biguanide is 1% or less by weight of the total amount of the PMMA bone cement.

8. The method of claim 7, wherein the PMMA bone cement admixture does not contain an antibiotic.

9. The method of claim 7, wherein the PMMA bone cement admixture does not adversely affect the wound-healing process in the long term and does not significantly impair the curing process of the bone cement.

10. The method of claim 7, wherein the active principle concentration of the polyhexamethylene biguanide is in an amount of from 0.025 to 0.5% by weight of the total amount of the PMMA bone cement.

11. The method of claim 10, wherein the active principal concentration of the polyhexamethylene biguanide is in a maximum amount of 0.155% by weight of the total amount of the cement.

12. A medical implant produced from bone cements according to claim 7.

13. The method of claim 8, wherein the PMMA bone cement admixture does not adversely affect the wound-healing process in the long term and does not significantly impair the curing process of the bone cement.

14. The method of claim 8, wherein the active principle concentration of the polyhexamethylene biguanide is in an amount of from 0.025 to 0.5% by weight of the total amount of the PMMA bone cement.

15. The method of claim 9, wherein the active principle concentration of the polyhexamethylene biguanide is in an amount of from 0.025 to 0.5% by weight of the total amount of the PMMA bone cement.

16. The method of claim 7, wherein the polyhexamethylene biguanide is an antiseptic.